title: Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.
abstract: In preparing for the threat of a pandemic of avian H5N1 influenza virus, we need to consider the significant delay (4 to 6 months) necessary to produce a strain-matched vaccine. As some degree of cross-reactivity between seasonal influenza vaccines and H5N1 virus has been reported, this was further explored in the ferret model to determine the targets of protective immunity. Ferrets were vaccinated with two intramuscular inoculations of trivalent inactivated split influenza vaccine or subcomponent vaccines, with and without adjuvant, and later challenged with a lethal dose of A/Vietnam/1203/2004 (H5N1) influenza virus. We confirmed that vaccination with seasonal influenza vaccine afforded partial protection against lethal H5N1 challenge and showed that use of either AlPO(4) or Iscomatrix adjuvant with the vaccine resulted in complete protection against disease and death. The protection was due exclusively to the H1N1 vaccine component, and although the hemagglutinin contributed to protection, the dominant protective response was targeted toward the neuraminidase (NA) and correlated with sialic acid cleavage-inhibiting antibody titers. Purified heterologous NA formulated with Iscomatrix adjuvant was also protective. These results suggest that adjuvanted seasonal trivalent vaccine could be used as an interim measure to decrease morbidity and mortality from H5N1 prior to the availability of a specific vaccine. The data also highlight that an inducer of cross-protective immunity is the NA, a protein whose levels are not normally monitored in vaccines and whose capacity to induce immunity in recipients is not normally assessed.
authors.affiliation: CSL Limited, Parkville, Victoria, Australia. steve.rockman@csl.com.au
authors.forename: Steven
authors.initials: S
authors.lastname: Rockman
authors.forename: Lorena E
authors.initials: LE
authors.lastname: Brown
authors.forename: Ian G
authors.initials: IG
authors.lastname: Barr
authors.forename: Brad
authors.initials: B
authors.lastname: Gilbertson
authors.forename: Sue
authors.initials: S
authors.lastname: Lowther
authors.forename: Anatoly
authors.initials: A
authors.lastname: Kachurin
authors.forename: Olga
authors.initials: O
authors.lastname: Kachurina
authors.forename: Jessica
authors.initials: J
authors.lastname: Klippel
authors.forename: Jesse
authors.initials: J
authors.lastname: Bodle
authors.forename: Martin
authors.initials: M
authors.lastname: Pearse
authors.forename: Deborah
authors.initials: D
authors.lastname: Middleton
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D056738:Cross Protection; D005289:Ferrets; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007273:Injections, Intramuscular; D009439:Neuraminidase / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D016019:Survival Analysis; D014764:Viral Proteins / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014764:Viral Proteins; C487630:NA protein, influenza A virus; D009439:Neuraminidase